Detalhe da pesquisa
1.
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Ann Neurol
; 76(6): 802-12, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25273271
2.
Anti-JC virus antibodies: implications for PML risk stratification.
Ann Neurol
; 68(3): 295-303, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20737510
3.
Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum.
J Immunol Methods
; 437: 53-63, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27555238
4.
A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
J Clin Virol
; 57(2): 141-6, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23465394
5.
Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma.
J Clin Virol
; 53(1): 65-71, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22104399
6.
Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4.
J Pharm Biomed Anal
; 55(1): 168-75, 2011 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-21300512
7.
A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
J Immunol Methods
; 352(1-2): 161-8, 2010 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-19891969